Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHP to sweeten bid?

This article was originally published in The Tan Sheet

Executive Summary

American Home Products will offer "additional value" to its bid for Warner-Lambert if W-L is able to secure the marketing rights to the blockbuster Rx cholesterol-reducer Lipitor, AHP says in a Nov. 30 letter to Warner-Lambert. W-L, which shares marketing rights to Lipitor with Pfizer, filed a counterclaim in Delaware chancery court Nov. 29 to end the partnership as a result of "massive and intentional breaches by Pfizer." In response, Pfizer says it has not violated any agreements and contends Warner-Lambert "has engaged in a series of desperate defensive measures." A court date on Pfizer's request to enjoin the proposed W-L/AHP merger is set for Jan. 24 (1"The Tan Sheet" Nov. 29, In Brief). W-L sent a letter to its shareholders Dec. 2 explaining the recent events and supporting a union with AHP

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel